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Ingrowth of aorta vascular cells into basic
fibroblast growth factor–impregnated vascular
prosthesis material: A porcine and human in vitro
study on blood vessel prosthesis healing
J. M. Annemieke van der Bas, MD,a,b Paul H. A. Quax, PhD,a,b Arjen C. van den Berg, BSc,a
Victor W. M. van Hinsbergh, PhD,a and J. Hajo van Bockel, PhD, MD,b Leiden, The Netherlands
Objective: One of the most life-threatening vascular diseases is rupture of an abdominal aneurysm. The conventional
treatment is based on surgical reconstruction. An alternative treatment is endovascular aneurysm repair (EVAR). Despite
many advantages, one of the problems of EVAR is endoleakage from deficient healing between the aortic neck and the
fabric of the endograft. We hypothesize that better healing, achieved with induction of vascular cell ingrowth into the
graft material, would lead to better graft healing.
Methods: Both pig aorta and human normal and aneurysmal aortic wall were used for organ cultures. Various growth
factors were evaluated for the potential to induce intimal hyperplasia (ie, platelet-derived growth factor, vascular
endothelial growth factor, and basic fibroblast growth factor [bFGF]). After the most potent growth factor had been
selected, a vascular prosthetic material (Dacron fabric) impregnated with collagen and heparin was incubated with this
growth factor. Impregnated pieces of Dacron were fixated on top of the aortic organ cultures for study of ingrowth of the
neointima formation into the graft material.
Results: bFGF was the most potent growth factor to induce neointima in aortic organ cultures. The pieces of impregnated
Dacron had a release of 5 ng/24 h of bFGF for a period of at least 28 days. With fixation on top of the aortic organ
cultures, the impregnated Dacron was capable of inducing neointima formation and ingrowth of the neointima into the
graft material after 28 days.
Conclusion: We showed that a Dacron prosthesis impregnated with collagen, heparin, and bFGF is capable of inducing
graft healing in our in vitro model, the aortic organ cultures of pig and human aortas. These results suggest that the
problem of endoleakage with EVAR may be solved with a perfect proximal healing between the aortic wall and the
prosthesis. (J Vasc Surg 2002;36:1237-47.)
One of the most life-threatening vascular diseases is
rupture of an abdominal aneurysm. Because the mortality
rate associated with acute rupture of an abdominal aneu-
rysm is high, treatment of the aneurysm before rupture is
important. A critical threshold to observe is the expansion
of the vessel wall to a diameter of more than 5 to 5.5 cm.1-3
The conventional treatment on the basis of surgical recon-
struction is effective but invasive. This operation is associ-
ated with a significant morbidity and mortality rate (3% to
7%).2,4,5 An alternative treatment is endovascular aneurysm
repair (EVAR), which is clearly less invasive with reduced
morbidity than the conventional surgery. The available data
on reduction of mortality rate range from 0 to 27%6-10 and
are far from conclusive yet. Despite the advantages of a
noninvasive technique, several problems in the use of
EVAR have still not been solved. One of the problems is
endoleakage,11-14 which is defined as leakage at the proxi-
mal stent of the endovascular prosthesis or as a backflow
into the aneurysm through one of the lumbar arteries. The
prevalence rate of leaks with bifurcated endografts was 18%,
and proximal and distal attachment leaks consisted of 44%,
resulting in a total of 8% attachment site endoleaks.15
Currently, the prevalence of type I endoleak is reportedly
lower (at 1 to 12 months, 3% to 4%).16,17 Proximal type I
endoleak may be related to expansion of the neck aneurysm
or migration of the device. In the Eurostar database, mi-
gration at the proximal and distal fixation sites has been
observed with an incidence rate that increases during fol-
low-up to up to 10% at 3 years after the operation. Migra-
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tion has also been identified as an independent risk factor
for rupture.18
One of the causes of endoleakage is imperfect sealing at
the proximal landing zone.19-21 A second cause is distal
migration during follow-up from deficient healing between
the aortic neck and the fabric of the endograft.17 Endoleak-
age leads to persisting pressure in the aneurysm, and rup-
ture has been reported as a cause of persisting endoleak.22 A
second problem of the deficient graft healing may be distal
graft migration,23 which may also cause endoleakage.
We hypothesize that better healing leads to better graft
fixation and reduces the incidence rate of endoleakage and
distal migration of endografts. Improved healing could be
achieved with the induction of vascular cell ingrowth into
the graft material. Here we study in organ cultures of
porcine and human aorta whether neointima formation and
ingrowth into the graft material can be induced with a basic
fibroblast growth factor (bFGF) containing collagen im-
pregnation of the graft material.
MATERIAL AND METHODS
Aortic wall organ culture. Both pig aortic wall and
normal and aneurysmal human aortic walls were used. Pig
aorta was obtained from pigs after death from the animal
laboratory and the local abattoir.
Normal aortic wall tissue from humans was obtained
from aortic samples that remained after organ transplanta-
tion. Aneurysmal aortic wall was obtained from humans
during abdominal aneurysm surgery. To this end, samples
were excised from the aneurysmal sac after removal of the
thrombus and after completion of the reconstruction. Pro-
cedures were in accordance with Human Ethics Committee
of the Leiden University Medical Center.
The culture of aorta pieces was done as described
previously.24,25 Briefly, segments were collected in sterile
Roswell Park Memorial Institute medium 1640 (Bio Whit-
taker Europe, Verviers, Belgium) supplemented with 20
mmol/L N-2-hydroethylpiperazine-N-2-ethanesulfonic
acid buffer, 4 IU/mL sodium heparin (Leo Pharmaceuti-
cals, Weesp, The Netherlands), 2.5 g/mL gentamicin,
100 U/mL penicillin, 100 g/mL streptomycin, 2
mmol/L L-glutamine, and 2.5 g/mL amphotericin B
(Bio Whittaker Europe). The segments were transported
on ice to the laboratory. Segments of aortic wall of porcine
and human origin were prepared with macroscopic and
gentle removal of the adventitia and fat tissue. The aorta
was opened along its longitudinal axis. A small piece was cut
off for analysis with histochemistry as t  0 reference
sample. The remaining part of the aorta was fixed with
needles in a petri dish coated with Sylgard 184 silicone
elastomer (Dow Corning, Seneffe, Belgium), with its en-
dothelial surface upward. The aortic segments were cul-
tured for a period of 4 to 5 weeks at 37° C in a humidified
atmosphere of 5% CO2 in the collection medium described
previously without heparin but supplemented with 30%
heat-inactivated fetal calf serum. The medium was replaced
every 2 to 3 days. Subsequently, various growth factors
were evaluated for their potential to induce intimal hyper-
plasia (ie, platelet-derived growth factor [PDGF], vascular
endothelial growth factor [VEGF], and bFGF [Peprotech,
Inc, London, England]). For the comparison experiment,
different segments of the same aorta were incubated with
one of the growth factors; PDGF (15 to 25 ng/mL),
VEGF (15 to 25 ng/mL), or bFGF (5, 10, 20, or 30
ng/mL) were added every time the culture medium was
replaced. To study the progression of neointima formation,
a small piece was cut off every week and fixed in 3.7%
formaldehyde. During culturing, each week, the margins
were cut off/removed from the aortic samples to prevent
overgrowth of fibroblasts from adventitia.
Immunohistochemistry. Paraffin-embedded tissue
was sectioned at 6 m. After dehydration, sections were
used either for histochemistry or immunohistochemistry.
For measurement of intima thickness, sections were stained
with hematoxylin, eosin, and saphran. Sections used for
immunohistochemistry were preincubated with 0.3%
H2O2 and 0.1% sodium azide in phosphate-buffered saline
solution (PBS) for 15 minutes to eliminate endogenous
peroxidase activity and rinsed with PBS. Sections were
incubated overnight at 4° C with monoclonal antibodies.
For identification of smooth muscle cells, a monoclonal
antibody was used that recognizes smooth muscle -actin
(Sigma, St Louis, Mo) at a 1:750 dilution. Bound mono-
clonal antibodies were detected with horseradish peroxida-
se–conjugated rabbit antimouse antibodies (1:300;
DAKO, Glostrup, Denmark). All antibodies were diluted
in PBS with 0.1% bovine serum albumin. The sections were
exposed for 4 minutes to 0.04% diaminobenzidine tetrahy-
drochloride in 0.05 mol/L trismaleate buffer (pH, 7.6)
with 0.006% H2O2. Sections were briefly counterstained
with hematoxylin.
Image analysis. From each organ culture, 18 histo-
logic sections were analyzed. Sections were taken segmen-
tally from the organ culture: three groups of six sections,
separated by 150 m. From 18 sections per organ culture,
the neointima area was measured. Per section, a minimum
of six randomly chosen high-power microscopic fields were
used for morphometric analysis of neointima area (Leica
QWin software, Leica Imaging Systems, Cambridge, En-
gland). From these six neointima measurements, the mean
per section was determined. Subsequently, the mean neo-
intima in the 18 sections was determined per organ culture
(thus, on the basis of 108 individual neointima measure-
ments). In total, 10 organ cultures per condition were
analyzed. In this way, we prevented biased analysis, and
accurate results were obtained. For determination of the
amount of neointima formation, analysis was performed
with image analysis (QWin, Leica Imaging Systems) in
histologic sections of the vessel segments. At different time
points, 7, 14, 21, 28, and 35 days, multiple sections per
segment (n  6) were evaluated. The neointima areas are
given in mm2 per microscopic field.
Vascular prosthetic material and coating. Vascular
prosthetic material was standard woven Dacron fabric used
for reconstructive surgery (Vascutek, Inchinnan, United
Kingdom). The porosity of the graft material evaluated was
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60 micron. With sterile conditions, the Dacron vascular
prosthetic material was impregnated with collagen as de-
scribed elsewhere.26-31 Briefly, type I insoluble collagen (1
g) derived from Bovine Achilles Tendon (Sigma) was swol-
len overnight in 0.52 mol/L acetic acid solution (50 mL) at
4° C. The mixture was dispersed with 50 g of crushed ice
for 4 minutes in a blender and thereafter homogenized for
30 minutes at 4° C with an Ultra-Turrax T25 (IKA
Labortechnik, Staufen, Germany). The resulting slurry was
filtered through a series of filters (Cellector Screen, Bellco,
Feltham, United Kingdom), with a pore size decreasing
from 140 m to 10 m, mounted in 47 mm-diameter
Swinnex disc filter holders (Millipore, Etten-Leur, The
Netherlands). After deaeration at a pressure of 0.06 milli-
bar, the resulting suspension was spread as a film on small
pieces of Dacron in sterile petri dishes and dried at room
temperature in a sterile flow cabin. The Dacron pieces,
impregnated with collagen were crosslinked with 0.731 g
N-(-3-dimethylaminopropyl)-N’-ethylcarbodiimide hy-
drochloride (EDC) and 0.415 g N-hydroxysuccinimide
(NHS). The cross linking was carried out in 215-mL buffer
of 2-morpholinoethane sulfonic acid buffer, 0.05 mol/L,
pH adjusted to 5.40 with 10 mol/L NaOH, to minimize
hydrolysis of EDC. After 4 hours, the cross linking was
completed and stopped with washing of the impregnated
Dacron with 0.1 mol/L Na2HPO4 solution for 2 hours.
(This treatment resulted in hydrolysis of both activated
carboxylic acid groups and remaining EDC.)
Binding and release of bFGF from collagen-heparin
impregnated Dacron fabric. After repeated washing
with sterile demineralized water (four times for 30 min-
utes), the Dacron, impregnated with cross-linked collagen,
was ready for heparin immobilization, essential for binding
the growth factor bFGF to the collagen impregnation.
Heparin sodium salt (Bufa Chemie, Castricum, The Neth-
erlands) was used. The carboxylic acid groups of heparin
(Hep-COOH) were activated with addition of EDC and
NHS to a 2% solution of heparin in 0.05 mol/L 2-morpho-
linoethane sulfonic acid buffer (pH, 5.60), at a molar ratio
of EDC:NHS:Hep-COOH of 0.4:0.24:1. After a 2-hour
reaction, the Dacron/collagen/heparin was washed with
0.1 mol/L Na2HPO4 for 2 hours, 4 mol/L NaCl for 4
hours, and distilled water for three times at 24 hours.
The binding of bFGF was carried out after incubation
of the Dacron/collagen/heparin in PBS. After blotting
dry, the films were incubated with 320 to 500 ng bFGF in
Fig 1. Cross sections of organ cultures of porcine aorta segments after 28 days in culture. A, Control sample: no
growth factor was added. B, Addition of PDGF (15 to 25 ng/mL) to culture medium did not stimulate neointima
formation. C, Lack of neointima formation when VEGF (15 to 25 ng/mL) was added. D, Neointima formation after
stimulation of segments with bFGF (10 ng/mL). Arrow indicates neointima layer.
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PBS containing 1 mg/mL bovine serum albumin for 90
minutes at room temperature.
The release of bFGF was tested in a release test where
every 24 hours a sample was obtained from the culture
media in which the Dacron/collagen/heparin/bFGF with
a diameter of 1 cm were placed. Every 24 hours, the
medium was replaced after a sample had been taken. The
concentration of bFGF in the release samples was deter-
mined with a sandwich enzyme-linked immunosorbent
assay (Quantikine bFGF ELISA, R&D Systems, Abingdon,
England).
Induction and quantification of ingrowth of neoin-
tima in prosthesis material. Experiments for inducing
ingrowth of neointima in the vascular prosthetic material
were performed as follows. Aortic tissue samples were ob-
tained as previously described and directly attached to
samples of 1 cm2 of impregnated Dacron. Experiments
were performed with nonimpregnated Dacron and colla-
gen/heparin impregnated Dacron (as control experiments
without growth factor) and collagen/heparin with growth
factor–impregnated Dacron. Dacron samples were at-
tached to the aortic samples with either needles or paper-
clips. Aortic samples of 2 cm2 were used. On top (the
luminal surface or “endothelial” side), samples of Dacron
fabric squares of 1 cm2 were placed. Subsequently, the
samples were cultured for up to 35 days. Also during
culturing, each week the margins were cut off/removed
from the aortic samples to prevent overgrowth of fibro-
blasts from adventitia.
After different time points (7, 14, 21, 28, and 35 days),
the organ cultures with the prosthetic material were har-
vested for evaluation with incubation of the tissue in for-
malin and paraffin. After histochemical staining as de-
scribed previously, the intima hyperplasia was evaluated
with computer-assisted image analysis as described previ-
ously. To assess the ingrowth into the Dacron, the area of
neointima formation and ingrowth was measured as de-
scribed previously.
Statistical analysis. Data are presented as mean 
standard error of the mean. Statistical analysis was per-
formed with the paired or unpaired two-tailed Student t
test. Statistical significance was accepted for a P value of less
than .05.
RESULTS
Induction of neointima formation in organ cultures
of pig and human aorta. In contrast to saphenous vein
organ cultures, cultures of aortic wall segments, either
those from human origin or those from porcine aortic wall,
do not spontaneously develop a neointima in standard
culture medium containing 30% fetal calf serum. However,
in the pig aorta organ cultures, intimal hyperplasia can be
induced with the addition of bFGF, 10 ng/mL, resulting in
a prominent neointima after 4 to 5 weeks in culture.
Application of other growth factors, such as VEGF or
PDGF (each at 15 to 25 ng/mL), had no effect on the
formation of neointima (Fig 1). Similar experiments were
performed with segments of human aorta in organ cultures.
Again, in human aortic organ cultures, a clear induction of
neointima was observed after 4 to 5 weeks in culture in the
presence of 10 ng/mL bFGF (Fig 2). However, VEGF or
PDGF (15 to 25 ng/mL) did not induce any neointima
formation. The efficacy of VEGF and PDGF was shown
previously in proliferation experiments with human endo-
thelial and smooth muscle cells.32,33 Because bFGF was the
only growth factor tested that induced a neointima in
porcine or human aortic organ cultures, all further experi-
ments were performed with bFGF.
Dose-dependent induction of intimal hyperplasia
with bFGF. For determination of the optimal concentra-
tion of bFGF for inducing neointima formation, porcine
and human aortic organ cultures were incubated with in-
creasing concentrations of bFGF. The optimal concentra-
tion of bFGF for inducing neointima formation in porcine
aortic organ cultures was between 10 and 20 ng/mL (Fig
Fig 2. Neointima formation in human atherosclerotic aortic wall segments after 35 days in organ culture. A, Control
organ culture (no growth factor added). B, Formation of neointima when bFGF (10 ng/mL) was added during period
of 35 days.
JOURNAL OF VASCULAR SURGERY
December 20021240 van der Bas et al
3). A concentration of 5 or 30 ng/mL bFGF induced less
neointima formation when compared with 10 or 20
ng/mL (P  .05). Because no significant difference in
neointima formation was found between 10 and 20 ng/mL
bFGF, all further experiments were performed with 10
ng/mL bFGF. The optimal concentration of bFGF for
inducing neointima formation in human, normal, and ath-
erosclerotic aortic organ cultures (10 to 20 ng/mL bFGF)
was similar to porcine organ cultures (data not shown).
Neointima formation in time. For study of the
development of the neointima formation induced by bFGF
(10 ng/mL) in porcine organ cultures in time, neointima
formation was measured at several time points. Fig 4 shows
the progression of neointima development during a 5-week
culture period. The first neointimal cell layers were already
detectable after 7 days. After 28 days, the growth of the
neointima seemed to slow down. No significant neointima
formation was observed from 14 days until 35 days of
incubation in the organ cultures without bFGF. Similar
results of the induction of neointima were observed in
human aorta organ cultures (0.35  0.02 mm2 after 35
days in culture).
Vascular prosthetic material: coating and bFGF
release. Two different prosthesis materials, Dacron and
polytetrafluoroethylene were evaluated for their suitability
to act as a substratum for cellular ingrowth by tissue seg-
ments. To achieve cellular ingrowth, complete impregna-
tion of the prosthetic material with the collagen and bFGF
was essential. Dacron was completely impregnated with the
collagen coating, whereas only a superficial coating with
collagen but no complete impregnation of the graft mate-
rial was achieved with polytetrafluoroethylene. Fig 5 shows
a representative cross section through the tested prosthesis
materials. Because total impregnation of the graft material
was a prerequisite for the adherence of the collagen coating
and cell ingrowth, all further experiments were performed
with impregnated 60-micron porosity Dacron. Polytetra-
fluoroethylene was not used for ingrowth experiments be-
cause collagen and polytetrafluoroethylene are not compat-
ible: collagen is hydrophobe, and polytetrafluoroethylene is
not. Coating of the Dacron material resulted in a 70%
increase of the graft thickness (292 45 m versus 172
25mforimpregnatedandnonimpregnatedDacronmaterial,
respectively).
Fig 3. Effect of different concentrations of bFGF was evaluated
with measurement of extent of neointima formation (ie, neointima
size) in porcine organ cultures. bFGF 10 and 20 ng/mL induced
similar extent of neointima formation. Neointima formation was
significantly less when 5 or 30 ng/mL bFGF was used. Expressed
as mean neointima area per cross section standard error of mean;
*P  .01. ns, Not significant.
Fig 4. Development of neointima in time (35 days). Neointima
formation in control organ cultures of porcine aorta segments
(hatched bars) and organ cultures stimulated with bFGF (10 ng/
mL; closed bars) were significantly different. Data represent mean
standard error of mean of neointima area per cross section; 18 cross
sections were analyzed per segment, and segments from 10 differ-
ent animals are used. *P  .01.
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First, the gradual release of bFGF from the collagen/
heparin coating was tested. In the first 3 days, a washout
effect was detected, followed by a stable release of bFGF of
5 to 8 ng/24 h per section (1 cm diameter) for 28 days (Fig
6). No major differences in long-term release could be
observed after prior loading of the collagen-heparin-coated
Dacron with either 300 or 500 ng bFGF. Binding bFGF to
collagen coating without heparin resulted in a quick release
of bFGF in 4 to 5 days (Fig 6), and after 5 days, no release
of bFGF could be detected.
Ingrowth of neointima in prosthesis. When organ
cultures were grown with an overlay of bFGF-coated Da-
cron pieces, the collagen layer disappeared with time and a
neointima developed. Cells from the neointima started to
migrate through the collagen-coated prosthesis material,
eventually resulting in a neointima on top of the prosthesis
material (Fig 7). The cells that had migrated were shown to
be smooth muscle cells that were -actin positive. The
induction of the neointima formation was only present in
porcine and human aorta organ cultures covered with
bFGF containing coated prosthesis material. Neointima
formation was absent in porcine aorta organ cultures with
pure Dacron, Dacron with collagen/heparin, and control
organ cultures without prosthesis material. The ingrowth
of pig aorta neointima through the Dacron was quantified
(Fig 8, A). The ingrowth of the neointima developed with
time. Experiments with human aorta organ cultures
showed comparable results. The normal human aortic or-
gan culture and the atherosclerotic human organ cultures
were both also capable of neointima formation, induced by
the bFGF-collagen impregnated Dacron. The cells of the
neointima in both the normal and aneurysmal aortic wall
were capable of growing in between the fibers of the
prosthetic material. Also, in human organ cultures, neoin-
tima formation and cellular invasion through the prosthetic
material could only be observed when the cultures were
covered with bFGF-coated Dacron prosthesis material. Af-
ter 5 weeks, the neointimal ingrowth was maximal and
resulted in a fixation of the graft material to the cultured
segments of the aorta vessel wall. The ingrowth of human
aorta neointima through the Dacron was quantified (Fig 8,
B).
DISCUSSION
The goal of this study was to achieve healing of a
vascular graft by inducing neointimal ingrowth of the arte-
rial vessel wall into the graft material. In this study, we were
able to show that neointima formation can be induced in
the aortic wall in organ cultures (both in human and
porcine aorta) with the application of bFGF. We found a
surprisingly low effect of bFGF in a concentration of 30
ng/mL. Furthermore, this induction of neointima forma-
tion was used to stimulate the ingrowth of vascular cells in
Dacron prosthesis material, which resulted in ingrowth and
improved graft healing. The induction of neointima forma-
tion in aorta arterial wall with growth factors has to our
Fig 5. Impregnation of pieces of Dacron and polytetrafluoroethylene with collagen. Dacron was completely impreg-
nated with collagen in contrast to polytetrafluoroethylene.
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knowledge not been reported before, although in organ
cultures of human internal mammary artery, intimal prolif-
eration can be induced.34 Induction of some neointima has
been reported in organ cultures of porcine aorta after a
period of 7 days with only fetal calf serum added. After this
period, the neointima formation stopped.35,36 This is in
contrast to the spontaneous neointima formation observed
in organ cultures of human saphenous vein segments with
only fetal calf serum added.24,25 We observed that aortic
organ cultures responded differently from vein organ cul-
tures. Aortic organ cultures needed the extra addition of
growth factor to induce the neointima, which spontane-
ously occurred in saphenous vein segments. We modified
the model and were able to induce neointima during a
period up to 35 days, which gave us the unique opportunity
to study neointimal hyperplasia and ingrowth in vitro dur-
ing a period up to 35 days. However, induction of neoin-
tima formation was only observed when bFGF was applied;
other growth factors had no stimulatory effect on neoin-
tima formation at all. In particular, neither PDGF nor
VEGF were effective in inducing any neointima. VEGF can
induce endothelial growth and angiogenesis but apparently
does not play a role in neointima formation in vitro.37 The
absence of a stimulatory effect of PDGF, a well-known
mitogen for cultured smooth muscle cells, to say the least is
surprising, and at this point, we have no explanation for the
lack of an effect of PDGF on neointima formation in vitro.
In the neointima formation induced with bFGF, cells were
morphologically identified as smooth muscle cells and
-smooth muscle actin positive fibroblastic cells that mi-
grated and probably differentiated into smooth muscle
cells. This identification was confirmed with immunohisto-
chemistry (-smooth muscle actin). No neointima forma-
tion could be observed next to the graft material positioned
in the middle of the vessel segments, indicating that migra-
tion was through the graft material and not via the side of
the segment as seen before in saphenous vein organ cul-
tures.24 After 28 days, the fibroblastic cells had almost all
transformed into smooth muscle cells, as has also been
shown before by Zalewski and Shi38 in their experiments on
mice during study of the differentiation and formation of
intima hyperplasia after vascular injury. In agreement with
Zalewski and Shi,38 we observed in our model that the
neointima became more organized in time. A nonorga-
nized neointima was encountered in the first 2 weeks,
which consisted of large -actin positive myofibroblast.
The rather “unorganized” structure of the neointima
highly resembled the initial stages of neointima formation
in saphenous vein grafts after coronary artery bypass graft-
ing in patients in whom at first instance a loosely organized
neointima is formed. In later stages, this develops into a
more organized neointima consisting of collagen deposits
and smooth muscle cell accumulation. An important and
clinically relevant observation was that both normal and
atherosclerotic aortic segments were able to form a neoin-
tima. This implies that even an atherosclerotic aorta wall
was able to mobilize the smooth muscle cells and fibroblast
from the media and adventitia to the neointima. The clin-
ical implication of this observation is that inducing a neo-
intima in atherosclerotic aortic wall is possible. This may
also help the healing of a vascular prosthesis. Because all
vessel wall segments (normal and aneurysmal) reacted in a
similar way, we presume the phenomenon we describe is a
more general phenomenon for aorta vessel wall. A disad-
vantage might be that the intimal hyperplasia could even-
tually cause a stenosis if progression of the lesion occurred.
However, we believe that the thickness of the neointima
induced in 1 month is not sufficient enough to cause
anastomotic stenosis. Neointima formation in the human
aorta could not only be induced by bFGF in normal seg-
ments, but also in atherosclerotic segments. This indicates
that this model of bFGF-induced neointima formation in
the aorta wall is useful for studying graft healing. To achieve
this goal, the Dacron material would have to be modified
with a neointima-inducing capacity (eg, with impregnation
with a neointima-stimulating growth factor).29,30
To deliver growth factors, a continuing local release
over a period of time must be achieved. The most obvious
carrier for this purpose is collagen. First, collagen has been
used experimentally to bind a number of medications (eg,
antibiotics). Second, collagen-coated grafts have been
widely used in clinical practice for a long time without
adverse effect.39 Third, the collagen is usually completely
Fig 6. Release of bFGF from collagen-impregnated Dacron
pieces (1 cm diameter). bFGF released from collagen-coated Da-
cron, either in presence of heparin (solid line) or without heparin
(dashed line), into culture medium was measured with enzyme-
linked immunosorbent assay. Rapid release of bFGF in absence of
heparin showed need for heparin for achieving controlled and
prolonged release of bFGF.
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Fig 7. In vitro ingrowth of neointimal tissue of porcine aorta wall into prosthesis material after 35 days. Ingrowth of
neointimal tissue into prosthesis material (A) was accompanied by partial disappearance of collagen around Dacron.
Neointima was growing completely through and on top of Dacron. B and C, Magnifications of neointima growing
through Dacron fibers (20 and 40, respectively).
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dissolved within several months.40 Dacron appears to be
the most ideal material to use in combination with collagen.
The impregnation of the Dacron with collagen was rela-
tively easy. The collagen was easily vacuumed through the
interstices of the porous graft material. The binding of
heparin to the collagen is necessary for the stabile binding
of bFGF,26,31 which results in a slow and controlled release
locally on the aortic segment. Dacron, impregnated with
collagen with the bFGF, but in the absence of heparin,
appeared not to be able to bind the growth factor for much
longer than 4 to 5 days.30 In contrast, Dacron impregnated
with collagen and heparin was capable of binding the bFGF
for at least 28 days and slowly releasing it into the culture
medium. This resulted in the constant local concentration
of 5 to 8 ng in 24 hours, a concentration that appeared to
be high enough to induce a substantial neointima. This
bFGF containing collagen/heparin impregnated Dacron
was capable of inducing neointima formation and thereby
ingrowth of the neointimal layers between the Dacron
fibers, resulting in an apparently tight fixation of the graft
material. Although this fixation was not analyzed quantita-
tively, the bFGF-containing collagen impregnated graft
material was the only variant that adhered to the vessel on
harvesting.
The described manipulation of the vascular pros-
thetic material has the potential to induce better healing
of vascular prosthetic material to the arterial wall. This
finding may have important implications for reconstruc-
tive surgery. It has been well known for a long time that
healing of vascular prosthesis to the arterial wall is in-
complete. Basically, only some pannus tissue arises as a
hyperplastic reaction from the ends to the host artery and
extends for a limited distance along the inner aspect of
the prosthesis in man.41 Later, healing was improved
with development of an external velour surface on the
Dacron graft. However, although healing in connective
tissue improved significantly, healing at the anastomotic
sites was still restricted to some pannus ingrowth as
described in previous studies.
There can only be speculation about the clinical impli-
cation of this impregnation with collagen/heparin/bFGF.
We emphasize this study is a first step in proving this
concept, and additional experiments are necessary. The
effects of bloodstream and shear stress on the prosthesis and
the release of bFGF are still unknown. We believe that the
release of bFGF into the bloodstream and the systemic
circulation will be small for several reasons. First, we as-
sumed a locally high concentration in the organ cultures
between the impregnated Dacron and the aortic wall be-
cause of a small release of bFGF into the culture medium.
Even if there is a little release of bFGF into the systemic
circulation, we believe that there will be no systemic effect
from the enormous dilution and the short half life of bFGF;
bFGF has also been studied for potential benefit to patients
with ischemia.42
However, that our study was an in vitro study and
that it still has to be determined whether intimal
hyperplasia can be induced in vivo and in the human
with atherosclerotically diseased arteries has to be ac-
knowledged. On the other hand, in contrast to the
control experiments without bFGF (which did not
show any intimal hyperplasia), both nondiseased and
aneurysmally changed aortas showed clearly intimal
Fig 8. Quantitative analysis of ingrowth of neointimal cells
formed pig (A) and human (B) aorta organ cultures into prosthesis
material. Collagen-impregnated pieces of Dacron were placed on
top of organ cultures. Ingrowth was measured after 5 weeks of
culture with analysis per cross section of area of neointima (mm2)
in contact with Dacron coated material. Seven segments from
different individuals were analyzed at each time point, four sections
per segment. All measurements were significantly different
(mean  standard error of mean; n  7; P  .01).
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hyperplasia. Another limitation of this in vitro study, the
time limit of 35 days that the organ cultures stayed alive,
means that there can only be a speculation about what
will happen in a period, for example, of 2 months.
Therefore, we expect that the next step (ie, animal
experiments) will help to further define intimal hyper-
plastic-induced healing.
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